Cell culture media market seen reaching $8.34B by 2030

The Business Research Company projects the global cell culture media and single-use reagents market will grow 13.6% annually to $8.34 billion by 2030. Rising investment in cell and gene therapy, more single-use bioprocessing and a shift to serum-free media are expected to drive demand.

Why it matters: - The market sits at the center of bioprocessing and biomanufacturing for advanced therapies. - Faster growth in cell and gene therapy manufacturing is increasing demand for sterile, scalable production inputs. - The shift toward single-use systems and defined media can improve contamination control and operational consistency.

What happened: - The Business Research Company published a 2026 report on the cell culture media and single-use reagents market. - The report says the market will grow from $4.41 billion in 2025 to $5 billion in 2026. - The report forecasts the market will reach $8.34 billion by 2030. - The report projects a 13.4% CAGR in the historical period and a 13.6% CAGR over the forecast period.

The details: - The market’s earlier growth was supported by serum-based cell culture systems, limited standardized GMP-grade reagents, reusable lab consumables, fragmented bioprocessing supply chains and early adoption of single-use technologies. - Forecast growth is tied to a move toward serum-free and chemically defined media. - Expansion of large-scale biomanufacturing facilities is another growth driver. - Rising adoption of single-use bioprocessing platforms is expected to support demand. - Increased investment in automated, high-throughput cell culture technologies is also part of the outlook. - The report says contamination-free aseptic processing, regulatory-compliant GMP-grade reagents and high-throughput screening platforms are emerging trends. - The report defines the market as nutrient media, buffers, supplements and pre-sterilized disposable consumables used to support cell growth, maintenance and processing. - These products are designed to support reproducible workflows in research labs and commercial biomanufacturing. - The report says North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa.

Between the lines: - Rising therapy investment is a key signal for suppliers because advanced therapies depend on controlled, contamination-sensitive manufacturing. - CGT Catapult reported that total investment in advanced therapies rose from £0.77 billion in 2023 to £0.97 billion in 2024, a 26% increase. - The report’s emphasis on single-use and GMP-grade inputs points to a market moving from general lab supply toward regulated, production-scale tooling.

What's next: - Demand is likely to track continued expansion in cell and gene therapy pipelines and biomanufacturing capacity. - The strongest growth appears likely in Asia-Pacific as production buildout accelerates. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards and trend analysis. - More information is available in the full report and a free sample.

The bottom line: - The market is moving from niche lab support to a core enabler of advanced biologics manufacturing, with double-digit growth expected through 2030.